Cost-Effectiveness of Digital Mental Health Versus Usual Care During Humanitarian Crises in Lebanon: Pragmatic Randomized Trial.

Lebanese Lebanon Syrian anxiety depression digital health digital mental health economic evaluation effectiveness internet-based intervention large randomized controlled trial mental health stress-related disorders symptoms treatment usual care

Journal

JMIR mental health
ISSN: 2368-7959
Titre abrégé: JMIR Ment Health
Pays: Canada
ID NLM: 101658926

Informations de publication

Date de publication:
29 May 2024
Historique:
received: 16 12 2023
accepted: 08 04 2024
revised: 22 03 2024
medline: 29 5 2024
pubmed: 29 5 2024
entrez: 29 5 2024
Statut: epublish

Résumé

There is evidence from meta-analyses and systematic reviews that digital mental health interventions for depression, anxiety, and stress-related disorders tend to be cost-effective. However, no such evidence exists for guided digital mental health care in low and middle-income countries (LMICs) facing humanitarian crises, where the needs are highest. Step-by-Step (SbS), a digital mental health intervention for depression, anxiety, and stress-related disorders, proved to be effective for Lebanese citizens and war-affected Syrians residing in Lebanon. Assessing the cost-effectiveness of SbS is crucial because Lebanon's overstretched health care system must prioritize cost-effective treatment options in the face of continuing humanitarian and economic crises. This study aims to assess the cost-effectiveness of SbS in a randomized comparison with enhanced usual care (EUC). The cost-effectiveness analysis was conducted alongside a pragmatic randomized controlled trial in 2 parallel groups comparing SbS (n=614) with EUC (n=635). The primary outcome was cost (in US $ for the reference year 2019) per treatment response of depressive symptoms, defined as >50% reduction of depressive symptoms measured using the Patient Health Questionnaire (PHQ). The secondary outcome was cost per remission of depressive symptoms, defined as a PHQ score <5 at last follow-up (5 months post baseline). The evaluation was conducted first from the health care perspective then from the societal perspective. Taking the health care perspective, SbS had an 80% probability to be regarded as cost-effective compared with EUC when there is a willingness to pay US $220 per additional treatment response or US $840 per additional remission. Taking the wider societal perspective, SbS had a >75% probability to be cost-saving while gaining response or remission. To our knowledge, this study is the first cost-effectiveness analysis based on a large randomized controlled trial (n=1249) of a guided digital mental health intervention in an LMIC. From the principal findings, 2 implications flowed, from the (1) health care perspective and (2) wider societal perspective. First, our findings suggest that SbS is associated with greater health benefits, albeit for higher costs than EUC. It is up to decision makers in health care to decide if they find the balance between additional health gains and additional health care costs acceptable. Second, as seen from the wider societal perspective, there is a substantial likelihood that SbS is not costing more than EUC but is associated with cost-savings as SBS participants become more productive, thus offsetting their health care costs. This finding may suggest to policy makers that it is in the interest of both population health and the wider Lebanese economy to implement SbS on a wide scale. In brief, SbS may offer a scalable, potentially cost-saving response to humanitarian emergencies in an LMIC. ClinicalTrials.gov NCT03720769; https://clinicaltrials.gov/ct2/show/NCT03720769. RR2-10.2196/21585.

Sections du résumé

BACKGROUND BACKGROUND
There is evidence from meta-analyses and systematic reviews that digital mental health interventions for depression, anxiety, and stress-related disorders tend to be cost-effective. However, no such evidence exists for guided digital mental health care in low and middle-income countries (LMICs) facing humanitarian crises, where the needs are highest. Step-by-Step (SbS), a digital mental health intervention for depression, anxiety, and stress-related disorders, proved to be effective for Lebanese citizens and war-affected Syrians residing in Lebanon. Assessing the cost-effectiveness of SbS is crucial because Lebanon's overstretched health care system must prioritize cost-effective treatment options in the face of continuing humanitarian and economic crises.
OBJECTIVE OBJECTIVE
This study aims to assess the cost-effectiveness of SbS in a randomized comparison with enhanced usual care (EUC).
METHODS METHODS
The cost-effectiveness analysis was conducted alongside a pragmatic randomized controlled trial in 2 parallel groups comparing SbS (n=614) with EUC (n=635). The primary outcome was cost (in US $ for the reference year 2019) per treatment response of depressive symptoms, defined as >50% reduction of depressive symptoms measured using the Patient Health Questionnaire (PHQ). The secondary outcome was cost per remission of depressive symptoms, defined as a PHQ score <5 at last follow-up (5 months post baseline). The evaluation was conducted first from the health care perspective then from the societal perspective.
RESULTS RESULTS
Taking the health care perspective, SbS had an 80% probability to be regarded as cost-effective compared with EUC when there is a willingness to pay US $220 per additional treatment response or US $840 per additional remission. Taking the wider societal perspective, SbS had a >75% probability to be cost-saving while gaining response or remission.
CONCLUSIONS CONCLUSIONS
To our knowledge, this study is the first cost-effectiveness analysis based on a large randomized controlled trial (n=1249) of a guided digital mental health intervention in an LMIC. From the principal findings, 2 implications flowed, from the (1) health care perspective and (2) wider societal perspective. First, our findings suggest that SbS is associated with greater health benefits, albeit for higher costs than EUC. It is up to decision makers in health care to decide if they find the balance between additional health gains and additional health care costs acceptable. Second, as seen from the wider societal perspective, there is a substantial likelihood that SbS is not costing more than EUC but is associated with cost-savings as SBS participants become more productive, thus offsetting their health care costs. This finding may suggest to policy makers that it is in the interest of both population health and the wider Lebanese economy to implement SbS on a wide scale. In brief, SbS may offer a scalable, potentially cost-saving response to humanitarian emergencies in an LMIC.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov NCT03720769; https://clinicaltrials.gov/ct2/show/NCT03720769.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) UNASSIGNED
RR2-10.2196/21585.

Identifiants

pubmed: 38810255
pii: v11i1e55544
doi: 10.2196/55544
doi:

Banques de données

ClinicalTrials.gov
['NCT03720769']

Types de publication

Journal Article Pragmatic Clinical Trial Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

e55544

Informations de copyright

©Racha Abi Hana, Jinane Abi Ramia, Sebastian Burchert, Kenneth Carswell, Pim Cuijpers, Eva Heim, Christine Knaevelsrud, Philip Noun, Marit Sijbrandij, Mark van Ommeren, Edith van’t Hof, Ben Wijnen, Edwina Zoghbi, Rabih El Chammay, Filip Smit. Originally published in JMIR Mental Health (https://mental.jmir.org), 29.05.2024.

Auteurs

Racha Abi Hana (R)

Clinical, Neuro- and Developmental Psychology Department, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
National Mental Health Programme, Ministry of Public Health, Beirut, Lebanon.

Jinane Abi Ramia (J)

Clinical, Neuro- and Developmental Psychology Department, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
National Mental Health Programme, Ministry of Public Health, Beirut, Lebanon.

Sebastian Burchert (S)

Division of Clinical Psychological Intervention, Department of Education and Psychology, Freie Universität Berlin, Berlin, Germany.

Kenneth Carswell (K)

Department of Mental Health and Substance Use, World Health Organization, Geneva, Switzerland.

Pim Cuijpers (P)

Clinical, Neuro- and Developmental Psychology Department, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
International Institute for Psychotherapy, Babeş-Bolyai University, Cluj-Napoca, Romania.

Eva Heim (E)

Institute of Psychology, University of Lausanne, Lausanne, Switzerland.
Department of Psychology, University of Zurich, Zurich, Switzerland.

Christine Knaevelsrud (C)

Division of Clinical Psychological Intervention, Department of Education and Psychology, Freie Universität Berlin, Berlin, Germany.

Philip Noun (P)

National Mental Health Programme, Ministry of Public Health, Beirut, Lebanon.

Marit Sijbrandij (M)

Clinical, Neuro- and Developmental Psychology Department, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.

Mark van Ommeren (M)

Department of Mental Health and Substance Use, World Health Organization, Geneva, Switzerland.

Edith Van't Hof (E)

Department of Mental Health and Substance Use, World Health Organization, Geneva, Switzerland.

Ben Wijnen (B)

Centre of Economic Evaluation and Machine Learning, Trimbos Institute (Netherlands Institute of Mental Health and Addiction), Utrecht, Netherlands.

Edwina Zoghbi (E)

Country Office for Lebanon, World Health Organization, Beirut, Lebanon.

Rabih El Chammay (R)

National Mental Health Programme, Ministry of Public Health, Beirut, Lebanon.
Faculty of Medicine, Psychiatry Department, Saint Joseph University, Beirut, Lebanon.

Filip Smit (F)

Clinical, Neuro- and Developmental Psychology Department, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Department of Epidemiology and Biostatistics, Amsterdam University Medical Centers, Amsterdam, Netherlands.
Department of Mental Health and Prevention, Trimbos Institute (Netherlands Institute of Mental Health and Addiction), Utrecht, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH